-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2024-512486-14-00
5
2026-01-22
Short Bowel Syndrome
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-521276-59-00
5
2025-12-16
Autosomal dominant polycystic kidney disease (ADPKD)
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-518006-40-00
5
2025-11-13
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-518973-32-00
5
2025-07-03
Chronic Graft-Versus-Host Disease
-
2024-511458-32-00
5
2025-06-15
Ulcerative colitis
-
2024-514517-35-00
5
2025-02-27
Acute myeloid leukemia
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2023-510022-33-00
5
2024-10-03
HIV-1 infection
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures
-
2022-501427-24-00
4
2023-04-25
Nonadvanced Systemic Mastocytosis
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-523914-10-00
6
2026-04-30
Critical illness
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced